Valion Bio, Inc. Financing Cash Flow
Valion Bio, Inc. (VBIO) reported Financing Cash Flow of $187.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Cash Flow › Financing Activities
us-gaap:NetCashProvidedByUsedInFinancingActivities · last filed 2026-08-14
- Valion Bio, Inc. net cash provided by (used in) financing activities for the quarter ending 2026-06-30 was $231.00K, a 90.22% decline year-over-year.
- Valion Bio, Inc. net cash provided by (used in) financing activities for the quarter ending 2026-03-31 was -$44.00K, a 153.66% decline year-over-year.
- Valion Bio, Inc. net cash provided by (used in) financing activities for the quarter ending 2025-12-31 was $11.63M, a 887.35% increase year-over-year.
- Valion Bio, Inc. net cash provided by (used in) financing activities for the quarter ending 2025-09-30 was $4.27M.
- Valion Bio, Inc. net cash provided by (used in) financing activities for fiscal 2025 was $18.35M, a 323.52% increase from fiscal 2024.
- Valion Bio, Inc. net cash provided by (used in) financing activities for fiscal 2024 was $4.33M, a 49.08% decline from fiscal 2023.
- Valion Bio, Inc. net cash provided by (used in) financing activities for fiscal 2023 was $8.51M.
- Valion Bio, Inc. net cash provided by (used in) financing activities for fiscal 2022 was -$528.00K, a 103.01% decline from fiscal 2021.
| Period end | Net Cash Provided by (Used in) Financing Activities 3 month | Net Cash Provided by (Used in) Financing Activities 6 month | Net Cash Provided by (Used in) Financing Activities 9 month | Net Cash Provided by (Used in) Financing Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $231.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | $187.00K 10-Q · filed 2026-08-14 | $11.82M derived: sum of 3 quarters · filed 2026-08-14 | $16.09M derived: sum of 4 quarters · filed 2026-08-14 |
| 2026-03-31 | -$44.00K 10-Q · filed 2026-05-14 | $11.59M derived: sum of 2 quarters · filed 2026-05-14 | $15.86M derived: sum of 3 quarters · filed 2026-05-14 | $18.22M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-12-31 | $11.63M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $15.90M derived: sum of 2 quarters · filed 2026-03-30 | $18.27M derived: sum of 3 quarters · filed 2026-08-14 | $18.35M 10-K · filed 2026-03-30 |
| 2025-09-30 | $4.27M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | $6.63M derived: sum of 2 quarters · filed 2026-08-14 | $6.72M 10-Q · filed 2025-11-14 | $7.89M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-06-30 | $2.36M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | $2.44M 10-Q · filed 2026-08-14 | $3.62M derived: sum of 3 quarters · filed 2026-08-14 | $3.52M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-03-31 | $82.00K 10-Q · filed 2026-05-14 | $1.26M derived: sum of 2 quarters · filed 2026-05-14 | $1.16M derived: sum of 3 quarters · filed 2026-05-14 | $4.47M derived: sum of 4 quarters · filed 2026-05-14 |
| 2024-12-31 | $1.18M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $1.08M derived: sum of 2 quarters · filed 2026-03-30 | $4.39M derived: sum of 3 quarters · filed 2026-03-30 | $4.33M 10-K · filed 2026-03-30 |
| 2024-09-30 | -$97.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | $3.21M derived: sum of 2 quarters · filed 2025-11-14 | $3.15M 10-Q · filed 2025-11-14 | $3.15M derived: sum of 4 quarters · filed 2025-11-14 |
| 2024-06-30 | $3.31M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | $3.25M 10-Q · filed 2025-08-14 | $3.25M derived: sum of 3 quarters · filed 2025-08-14 | $7.63M derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | -$61.00K 10-Q · filed 2025-05-15 | -$61.00K derived: sum of 2 quarters · filed 2025-05-15 | $4.32M derived: sum of 3 quarters · filed 2025-05-15 | $4.28M derived: sum of 4 quarters · filed 2025-05-15 |
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-21 | $4.38M derived: sum of 2 quarters · filed 2025-03-21 | $4.34M derived: sum of 3 quarters · filed 2025-03-21 | $8.51M 10-K · filed 2025-03-21 |
| 2023-09-30 | $4.38M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | $4.34M derived: sum of 2 quarters · filed 2024-11-14 | $8.51M 10-Q · filed 2024-11-14 | $7.92M derived: sum of 4 quarters · filed 2024-11-14 |
| 2023-06-30 | -$44.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | $4.13M 10-Q · filed 2024-08-14 | $3.54M derived: sum of 3 quarters · filed 2024-08-14 | |
| 2023-03-31 | $4.17M 10-Q · filed 2024-05-15 | $3.59M derived: sum of 2 quarters · filed 2024-05-15 | ||
| 2022-12-31 | -$584.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-25 | -$528.00K 10-K · filed 2024-03-25 | ||
| 2022-09-30 | $56.00K 10-Q · filed 2023-11-14 | |||
| 2021-12-31 | $14.89M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-31 | $15.76M derived: sum of 2 quarters · filed 2023-03-31 | $17.32M derived: sum of 3 quarters · filed 2023-03-31 | $17.54M 10-K · filed 2023-03-31 |
| 2021-09-30 | $869.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | $2.44M derived: sum of 2 quarters · filed 2022-11-14 | $2.66M 10-Q · filed 2022-11-14 | |
| 2021-06-30 | $1.57M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-15 | $1.79M 10-Q · filed 2022-08-15 | ||
| 2021-03-31 | $221.00K 10-Q · filed 2022-05-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |